2026-10-14T11:20:40Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34047406 2026-10-01T17:23:18Z category_7 category_8 category_21 category_39 category_46 category_811 category_64 category_132 category_134 category_135 portal_5 item_type_1 month_year_10_2026

<p>Schematic showing the multiple levels of the <i>serosolver</i> model.</p> Mhairi J. McCormack (25157587) Louis Banda (5632649) Stephen Kasenda (6844046) Ellen C. Hughes (25157590) Amelia Crampin (272631) Abena S. Amoah (8605329) Jonathan M. Read (9159869) Antonia Ho (10214054) Brian J. Willett (11450469) James A. Hay (6066002) Medicine Microbiology Biotechnology Ecology Immunology Mathematical Sciences not elsewhere classified Cancer Infectious Diseases Virology Computational Biology level bayesian model boosting following reinfection april 2022 ). acute boost remaining accurate epidemiological inference 403 &# 8211 027 &# 8211 rapid waning underscores 679 neutralising antibody reconstruct infection histories quantify antibody kinetics limited routine surveillance particularly among adults malawi </ p infection histories routine surveillance antibody waning antibody kinetics uninfected participants understanding transmission traditional seroconversion three months sustained protection serological measurements saharan africa responses varied regional differences reactivity suggests prior variants one year measured using individuals clustering improved understanding high responders finding populations declined rapidly complicating interpretation based thresholds ancestral b analysed 15 675 unvaccinated 41 vs <p>(A) The model describes the probability of SARS-CoV-2 infection over time. (B) Infections are modelled as Bernoulli trials from the nfection probability model in (A), resulting in longitudinal neutralising antibody (nAb) titres. This example shows predicted antibody titres to variant X (blue) for a participant first infected with variant X and later with variant Y. (C) The model captures cross-reactive antibody response to all variants. Shown here are nAb titres to variant Y (pink) over time, compared to variant X (blue, dotted), with sampling points for two longitudinal measurements indicated. (D) The antigenic map determines cross-reactivity between variants, here depicting the Euclidean distance between variants X and Y. (E–F) nAb titres measured against variants X (blue) and Y (pink) at the first (E) and second (F) sample collection. Created with Biorender.com.</p> <p>(PNG)</p> 2026-10-01T17:23:08Z Image Figure 10.1371/journal.pgph.0007133.s007 https://figshare.com/articles/figure/_p_Schematic_showing_the_multiple_levels_of_the_i_serosolver_i_model_p_/34047406 CC BY 4.0